Netherlands Study Finds Estrogen Increases Male Breast Cancer Rate 46 Times

They're selling this to children.

Here is a link to the abstract.

This study, which is specifically looking at transgender individuals, found that men who were given estrogen had a rate of breast cancer 46 times the base rate of men who had not taken a drug known to make breasts grow and breast cancers also therefore grow. This is not remotely a subtle effect. The same study found that testosterone use in females was correlated with a lower rate of breast cancer, which makes little sense until you remember they are cutting their breasts off at the start of treatment, before they’re out of middle school. Because THEY KNOW. They know it will give them breast cancer. And they know it’ll give them reproductive cancers.

There’s a reason they’re so eager to do these gender-affirming hysterectomies, and why they’re desperate to cover it up. They know the girls who opt not to get these interventions will get cancer and eventually, the truth will come out. It will be impossible to ignore. Everyone who knows trans people will find themselves burying friends in their twenties and thirties, not because of transphobia, but because of their drug-induced genetic illness. Please see my essay or listen to my podcast regarding my night of dialectical ethnography on twitter for a detailed description of what’s at the end of the road for untreatable cancer in a major organ system.

They know. We know. They know we know. We know they know. They know we know they know. We know they know we know. We’re looking at each other, watching them hurt children. Who will stand up and demand that they stop?

Shame on the toilet comedians who did not bother to google “testosterone cancer.” Especially Jon “I care so much about cancer-ridden first responders” Stewart.

Results: The total person time in this cohort was 33 991 years for trans women and 14 883 years for trans men. In the 2260 trans women in the cohort, 15 cases of invasive breast cancer were identified (median duration of hormone treatment 18 years, range 7-37 years). This was 46-fold higher than in cisgender men (standardised incidence ratio 46.7, 95% confidence interval 27.2 to 75.4) but lower than in cisgender women (0.3, 0.2 to 0.4). Most tumours were of ductal origin and oestrogen and progesterone receptor positive, and 8.3% were human epidermal growth factor 2 (HER2) positive. In 1229 trans men, four cases of invasive breast cancer were identified (median duration of hormone treatment 15 years, range 2-17 years). This was lower than expected compared with cisgender women (standardised incidence ratio 0.2, 95% confidence interval 0.1 to 0.5).